Sograzepide|155488-25-8|(Netazepide; YF 476; YM-220)-陌孚医药/Medlife

您当前的位置：

Sograzepide (Synonyms: Netazepide; YF 476; YM-220)

目录号: PL04279 纯度: ≥98%

CAS No. :155488-25-8

商品编号	规格	价格	会员价
PL04279-5mg	5mg	¥3090.91	请登录
PL04279-10mg	10mg	¥5563.64	请登录
PL04279-50mg	50mg	¥17309.09	请登录
PL04279-100mg	100mg	¥25963.64	请登录
PL04279-200mg	200mg	询价	询价
PL04279-500mg	500mg	询价	询价
PL04279-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3400.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Sograzepide
中文别名	N-[(3R)-1-(3,3-二甲基-2-氧代丁基)-2,3-二氢-2-氧代-5-(2-吡啶基)-1H-1,4-苯并二氮杂卓-3-基]-N'-[3-(甲基氨基)苯基]脲;N-苄氧羰基-L-谷氨酸-5-苄脂
英文名称	Sograzepide
英文别名	N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea;1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea;Sograzepide;(R)-1-[2,3-Dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea;1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea;Urea,N-[1-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]-,(R)-;YF 476;Estradiol-3-O-sulfamate
Cas No.	155488-25-8
分子式	C₂₈H₃₀N₆O₃
分子量	498.58
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Sograzepide (Netazepide; YF 476; YM-220) 是一种非常有效，高选择性和口服活性的 Gastrin/CCK-B 拮抗剂，IC₅₀ 值为 0.1 nM，还抑制 Gastrin/CCK-A 活性， IC₅₀ 值为 502 nM。Sograzepide (Netazepide; YF 476; YM-220) 取代 [125I]CCK-8 与大鼠脑，克隆犬和人 Gastrin/CCK-B 的特异性结合，K_i 值分别为 0.068、0.62 和 0.19 nM。

生物活性

Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC 50 of 502 nM. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K i values of 0.068, 0.62 and 0.19 nM, respectively.

性状

Solid

IC50 & Target[1][2]

IC50: 0.1 nM (Gastrin/CCK-B); 501 nM (Gastrin/CCK-A)

体内研究(In Vivo)

Sograzepide (Netazepide; YF 476; YM-220) (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anethsetized rats with an ED 50 of 87?nmol/kg.
Sograzepide (Netazepide; YF 476; YM-220) (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion with an ED 50 value of 0.0086 μM/kg, but does not affect histamine- and bethanechol-induced acid secretion.
Sograzepide (Netazepide; YF 476; YM-220) (intravenous injection; oral administration) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner with ED 50 values of 0.018 and 0.020 μM/kg, respectively . has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55.
[2]. Takinami Y, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.Aliment Pharmacol Ther. 1997 Feb;11(1):113-20.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (200.57 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation